Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28

Wells Fargo analyst Larry Biegelsen has initiated coverage on Beta Bionics (NASDAQ: BBNX) with an Overweight rating. The firm has set a price target of $28 for the company's stock.